FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Q BioMed Technology Partner Mannin Research Inc. Presents Data Showing Potential Treatment to Protect the Kidney in Acute Kidney Injury Using Mannin Tie2 Activator.”
Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, is announcing today that its technology research partner Mannin Research Inc. (Mannin) presented positive data on a potential new treatment for acute kidney injury (AKI). The data was presented at the American Society for Nephrology 2019 Annual Meeting held in Washington DC.
Q BioMed Inc. is a biotech acceleration and commercial stage company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need.
In 2017, the Institute for Health Metrics and Evaluation (IHME) said in a report that a total of 359 diseases and injuries were added to the fatal and non-fatal list of conditions since 1950. According to data by the Global Burden of Diseases, the most common causes of fatalities are heart conditions, stroke, respiratory infections, lung diseases, Alzheimer’s, diabetes, and kidney diseases. While some of these cases are difficult to prevent, most medical conditions can be treated in order to suppress the severity of maladies, or even potentially eliminate them. For instance, patients suffering from cancer can undergo chemotherapy in order to prolong life expectancy or reduce symptoms. However, even before a person can develop an ailment, advanced medical technologies can perform genetic screenings to help identify possible increased risks of developing certain diseases. On the other hand, in some instances, the development of the disease can be deadly and will most likely require some kind of highly advanced treatment or even transplant. Additionally, the plethora of biotechnological therapies now available to patients has helped to completely reshape the global health outlook. And as such, the ever-growing number of diseases worldwide will continue to expand the biotechnology market as more countries demand effective and efficient treatment solutions. According to data compiled by Variant Market Research, the global biotechnology market is projected to reach USD 726.8 Billion by 2025 while witnessing a CAGR of 8.1% from 2017 to 2025.
Notably, kidney diseases are one of the most common diseases in the U.S., affecting nearly 37 million people, according to the National Kidney Foundation. The organization notes that roughly 90% of people usually do not know they have some sort of kidney disease. And the organization also mentions that about one in three Americans are at risk of kidney disease. Consequently, it is the ninth leading cause of death in the U.S. The organization highlighted that in 2016, over 500,000 patients received dialysis treatment, and over 200,000 survived with a kidney transplant. Typically, the most common kidney diseases are either acute kidney injury or chronic kidney disease, according to the National Institute of Diabetes and Digestive and Kidney Diseases. Acute kidney injury is defined as a sudden and temporary loss of kidney functions, while chronic kidney disease is known as any condition that causes reduced kidney function over a period of time, according to the institute. Chronic kidney disease is classified into five stages that occur over a period of time, however, an acute kidney injury can potentially happen within just a few hours or even several days. Acute kidney injury causes a build-up of waste products in the bloodstream, making it difficult for the kidneys to keep the right balance of fluid. If acute kidney injury goes untreated, patients run the risk of affecting other organs such as their brain, heart and lungs. Predominantly, acute kidney injury is treated in the hospital in intensive care units. “Your kidneys, like every other organ in your body, have multiple jobs. They’re deeply connected to the rest of your body. Their main function is to filter waste out of your blood. They also remove extra fluid from your blood (this becomes urine) and control blood pressure. Kidneys help make red blood cells. They regulate electrolytes (a type of nutrient) and activate vitamin D, too,” said WebMD. “Acute kidney failure isn’t always permanent. If you get treatment right away — and if you don’t have other serious health problems — your kidneys may go back to working like normal.”
For more information, please visit: Q BioMed Inc.
For more corporate news on Q BioMed Inc., check out the Buzz on the Street
About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.